Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China

• by Wanyan Xiang, Jiarong Lu, Siqi Zhang, Wenjun Zheng, Qiuju Li

• July 6, 2026

Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis

• by Jonathan I. Silverberg, Eric L. Simpson, Saleem A. Farooqui, Gary Chan, Pinaki Biswas, Erman Güler

• May 20, 2026

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

• by Andrea Surnit

• May 20, 2026

• 4 min

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

• by Andrea Surnit

• July 6, 2026

• 3 min